Recent approvals of immune checkpoint inhibitors with companion PD-L1 IHC assays in various tumor types demonstrate the increasing utility and widespread clinical use of PD-L1 testing to determine patients who may benefit from these therapies. This evidence concerns the gene CD274 and neoplasm.